"Big Banks" Bank of America Securities: The progress of two drugs from SINO BIOPHARM is positive, reiterating a "Buy" rating
The Bank of America Securities research report indicates that SINO BIOPHARM (01177.HK) has recently completed the enrollment of subjects for the Phase III clinical trials of two drugs, TQB2102 and LM302. Among them, LM302 is the world's first CLDN18.2 antibody-drug conjugate to complete subject enrollment for Phase III registration clinical trials, which is expected to provide new treatment options for patients. The firm currently sets a target price of HKD 8.6 and reaffirms its "Buy" rating
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments